Abstract
Currently vildagliptin can be used for treating type 2 diabetes mellitus (T2DM) as a first-line monotherapy. The main adverse drug events which have been reported with the use of vildagliptin include nausea, loss of appetite, diarrhea, peripheral edema, headache, dizziness and upper respiratory infection. This study was conducted to determine possible association between the TCF7L2 rs7903146 (C >T) polymorphism and adverse drug effects (ADE) occurrence among patients with newly diagnosed T2DM treated with vildagliptin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
